DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner

Virology

Volumn 351, Issue 1, 2006, Pages 159-169

  Miller, Darren S ^a   Kotlarski, Ieva ^a   Jilbert, Allison R ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Cell mediated immunity; DHBV surface antigen; DNA vaccine; Duck hepatitis B virus; Human hepatitis B virus; Humoral immunity

Indexed keywords

CELL SURFACE PROTEIN; DNA VACCINE; MEMBRANE ANTIGEN; PLASMID DNA; PLASMID VECTOR; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DUCK; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; LIVER BIOPSY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VACCINATION; VIRUS GENOME; VIRUS INFECTION;

ANAS; DUCK HEPATITIS B VIRUS;

EID: 33745852568     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.02.037     Document Type: Article

References (26)

1. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2 8 (2001) 675-680
2. Bertoletti A., and Naoumov N.V. Translation of immunological knowledge into better treatments of chronic hepatitis B. J. Hepatol. 39 1 (2003) 115-124
3. Davis H.L., Brazolot Millan C.L., Mancini M., McCluskie M.J., Hadchouel M., Comanita L., Tiollais P., Whalen R.G., and Michel M.L. DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice. Vaccine 15 8 (1997) 849-852
4. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., and Weeranta R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160 2 (1998) 870-876
5. Foster W.K., Miller D.S., Scougall C.A., Kotlarski I., Colonno R.J., and Jilbert A.R. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection. J. Virol. 79 9 (2005) 5819-5832
6. Jilbert A.R., Wu T.T., England J.M., Hall P.M., Carp N.Z., O'Connell A.P., and Mason W.S. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 66 3 (1992) 1377-1388
7. Jilbert A.R., Miller D.S., Scougall C.A., Turnbull H., and Burrell C.J. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 226 2 (1996) 338-345
8. Jilbert A.R., Botten J.A., Miller D.S., Bertram E.M., Hall P.M., Kotlarski J., and Burrell C.J. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection. Virology 244 2 (1998) 273-282
9. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatitis 11 2 (2004) 97-107
10. Lu M., Hilken G., Kruppenbacher J., Kemper T., Schirmbeck R., Reimann J., and Roggendorf M. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J. Virol. 73 1 (1999) 281-289
11. Maugh T.H. FDA approves hepatitis B vaccine. Science 214 4525 (1981) 1113
12. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 6640 (1997) 394-397
13. Meier P., Scougall C.A., Will H., Burrell C.J., and Jilbert A.R. A duck hepatitis B virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo growth characteristics to wild-type virus. Virology 317 2 (2003) 291-298
14. Michel M.L., Pol S., Brechot C., and Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 19 17-19 (2001) 2395-2399
15. Miller D.S., Bertram E.M., Scougall C.A., Kotlarski I., and Jilbert A.R. Studying host immune responses against duck hepatitis B virus infection. Methods Mol. Med. 96 (2004) 3-26
16. Miller, D.S., Halpern, M., Kotlarski, I., Jilbert, A.R., in press. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection. Virology (Electronic publication ahead of print, 2006 Feb. 6).
17. Prince A.M., Whalen R., and Brotman B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 15 8 (1997) 916-919
18. Pugh J.C., Di Q., Mason W.S., and Simmons H. Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles. J. Virol. 69 8 (1995) 4814-4822
19. Rollier C., Sunyach C., Barraud L., Madani N., Jamard C., Trepo C., and Cova L. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 116 3 (1999) 658-665
20. Rollier C., Charollois C., Jamard C., Trepo C., and Cova L. Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein. Vaccine 18 27 (2000) 3091-3096
21. Rollier C., Charollois C., Jamard C., Trepo C., and Cova L. Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection. J. Virol. 74 10 (2000) 4908-4911
22. Surelia P., and Boxall E.H. Hepatitis B virus infection: detection of circulating HBsAg/IgM antibody immune complexes. Med. Lab. Sci. 47 3 (1990) 204-209
23. Triyatni M., Jilbert A.R., Qiao M., Miller D.S., and Burrell C.J. Protective efficacy of DNA vaccines against duck hepatitis B virus infection. J. Virol. 72 1 (1998) 84-94
24. Triyatni M., Ey P., Tran T., Le Mire M., Qiao M., Burrell C., and Jilbert A. Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses. J. Gen. Virol. 82 Pt. 2 (2001) 373-378
25. Tsai J.F., Margolis H.S., Jeng J.E., Ho M.S., Chang W.Y., Lin Z.Y., and Tsai J.H. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin. Immunol. Immunopathol. 75 1 (1995) 39-44
26. Tsai J.F., Margolis H.S., Jeng J.E., Ho M.S., Chang W.Y., Hsieh M.Y., Lin Z.Y., and Tsai J.H. Immunoglobulin- and hepatitis B surface antigen-specific circulating immune complexes in chronic hepatitis B virus infection. Clin. Immunol. Immunopathol. 86 3 (1998) 246-251